Why We’re Keeping Our $700 Price Target on This Holding as Shares Drop
Let’s break down the latest earnings and guidance, why the stock’s moving lower today and our plan going forward.
I’m Eyeing 2 Biopharma Stocks Amid Choppy Market Action
These small-cap biotechs offer core businesses that fund a much bigger opportunity.
Inseego Reports, and My Question Is: What Was I Thinking?!
Here’s how I’m handling this holding after a dismal report … and why I’m adding to another name that has the right ‘ingredients.’
The Surprising Tesla-SpaceX Correlation Investors Can’t Ignore
Tesla and SpaceX share more than a CEO. Here’s what SpaceX’s lockup expiration could mean for Tesla stock.
I See Two Very Different Opportunities in This Overbought Market
I’m getting into a legacy technology stock and an up-and-coming biopharma. Here’s why.
Here’s My AMD Plan After Wall Street’s ‘Misguided’ Selloff
What exactly are AMD bears hanging their hats on? Oh, and I have allies…
Market Starts to Roll Over as Dip Buyers Step Away
Underinvested longs were buying shallow dips, which is what keeps a strong market sticky.
Buying More Rocket Lab After $397 Million Update
The aerospace firm has been awarded a significant contract by the U.S. Space Force.
We’re Initiating New Positions in 2 ETFs
Following our cybersecurity strategy, we’re bringing new end-market exposures to the Portfolio.
